Sanofi's Q1 Earnings Slightly Surpass Expectations Before CEO Transition

• Total Q1 sales reached 10.51 billion euros ($12.29 billion), surpassing analyst estimates of 10.22 billion euros, with operating income of 2.97 billion euros beating the 2.85 billion euro forecast
• Dupixent sales rose 30.8% at constant exchange rates to 4.17 billion euros ($4.88 billion), significantly exceeding analyst expectations of 3.89 billion euros for the quarter
• The strong results arrive amid leadership change as a new CEO takes over at end of April following Paul Hudson's February exit after failing to reduce company reliance on Dupixent

Summary

Financial Performance:

French pharmaceutical giant Sanofi reported Q1 2026 results exceeding analyst expectations on April 23. Total sales reached €10.51 billion ($12.29 billion) for the quarter ended March 31, surpassing the €10.22 billion consensus estimate. Business operating income hit €2.97 billion ($3.47 billion), above the €2.85 billion forecast.

Key Driver:

The standout performer was Dupixent, Sanofi's blockbuster asthma and eczema treatment developed with U.S. partner Regeneron. Sales surged 30.8% at constant exchange rates to €4.17 billion ($4.88 billion), significantly exceeding analyst predictions of €3.89 billion. Dupixent's resilient demand accounted for approximately 40% of total quarterly revenue.

Leadership Transition:

The results arrive during a critical leadership change. Former CEO Paul Hudson departed in February 2026 after struggling to diversify the company's drug pipeline and reduce dependence on Dupixent. His tenure was marked by disappointing clinical trial results for potential alternative products. A new CEO is scheduled to assume leadership at the end of April 2026.

Guidance:

Sanofi reaffirmed its full-year outlook, though specific targets were not detailed in the report.

Market Implications:

The strong Q1 performance, particularly Dupixent's continued momentum, provides a positive foundation for the incoming CEO. However, the company faces ongoing challenges in developing pipeline alternatives to offset future patent expirations and market competition. Investors will watch closely how new leadership addresses these strategic concerns while capitalizing on current revenue strength.